Jeroen Verheyen

Jeroen Verheyen is the Co-Founder and CEO of Semarion, a company operating at the intersection of emerging technologies and life sciences.1 He is actively involved in the development and promotion of Semarion's innovative technologies, particularly their SemaCyte® platform.2

Professional Background

Verheyen has a strong educational foundation, having studied at the University of Cambridge.1 His expertise lies in bridging the gap between cutting-edge technologies and their applications in the life sciences sector.

Achievements and Recognition

Industry Awards:: In 2024, Semarion, under Verheyen's leadership, won the SLAS Europe Ignite Award.2 This recognition highlights the company's innovative contributions to the field.

Personal Accolades:: In 2022, Verheyen was named in cofinitive's #21toWatch final Top21.2022, acknowledging his potential as a rising innovator in the industry.3

Professional Activities

Verheyen is actively engaged in promoting Semarion's technologies and participating in industry events:

• He has given interviews discussing the transformative potential of Semarion's SemaCyte® technology.2
• Semarion participates in events like ELRIG UK's Research & Innovation conference, showcasing their novel technologies to the drug discovery community.4
• Verheyen advocates for the adoption of new innovations in drug discovery, particularly in the TechBio sector.5

Through his role at Semarion, Jeroen Verheyen is working to advance technologies that have the potential to significantly impact drug discovery and life sciences research.